BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32255798)

  • 1. Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis.
    Sun Y; Wan G; Liang L
    PLoS One; 2020; 15(4):e0231110. PubMed ID: 32255798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
    Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
    Trials; 2018 May; 19(1):264. PubMed ID: 29720244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Taurolidine, an antiseptic for the prevention of central venous catheter-related infections].
    Haro C
    Rev Chilena Infectol; 2019 Aug; 36(4):414-420. PubMed ID: 31859763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.
    Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB
    Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993
    [No Abstract]   [Full Text] [Related]  

  • 5. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.
    Klek S; Szczepanek K; Hermanowicz A; Galas A
    JPEN J Parenter Enteral Nutr; 2015 Mar; 39(3):331-5. PubMed ID: 24604029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of the efficacy of taurolidine in reducing catheter-related bloodstream infections for patients receiving parenteral nutrition.
    Vernon-Roberts A; Lopez RN; Frampton CM; Day AS
    JPEN J Parenter Enteral Nutr; 2022 Sep; 46(7):1535-1552. PubMed ID: 35233792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition.
    Al-Amin AH; Sarveswaran J; Wood JM; Burke DA; Donnellan CF
    J Vasc Access; 2013; 14(4):379-82. PubMed ID: 23817948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients.
    Neusser MA; Bobe I; Hammermeister A; Wittmann U
    Br J Nurs; 2021 Jul; 30(14):S24-S32. PubMed ID: 34288746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized, Double-Blind, Placebo-Controlled Trial (TAURCAT Study) of Citrate Lock Solution for Prevention of Endoluminal Central Venous Catheter Infection in Neutropenic Hematological Patients.
    Gudiol C; Arnan M; Aguilar-Guisado M; Royo-Cebrecos C; Sánchez-Ortega I; Montero I; Martín-Gandul C; Laporte-Amargós J; Albasanz-Puig A; Nicolae S; Perayre M; Berbel D; Tebe C; Riera J; Sureda A; Cisneros JM; Carratalà J
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.
    Handrup MM; Møller JK; Schrøder H
    Pediatr Blood Cancer; 2013 Aug; 60(8):1292-8. PubMed ID: 23417891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 2% taurolidine lock solution for treatment and prevention of catheter-related bloodstream infections in neonates: a feasibility study.
    Savarese I; Yazami S; De Rose DU; Carkeek K; Campi F; Auriti C; Danhaive O; Piersigilli F
    J Hosp Infect; 2024 Jan; 143():76-81. PubMed ID: 37972710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials.
    Liu Y; Zhang AQ; Cao L; Xia HT; Ma JJ
    PLoS One; 2013; 8(11):e79417. PubMed ID: 24278133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethanol lock is effective on reducing the incidence of tunneled catheter-related bloodstream infections in hemodialysis patients: a systematic review and meta-analysis.
    Zhao T; Liu H; Han J
    Int Urol Nephrol; 2018 Sep; 50(9):1643-1652. PubMed ID: 29667048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catheter lock solutions for reducing catheter-related bloodstream infections in paediatric patients: a network meta-analysis.
    Guo Q; Lv Z; Wang H; Song L; Liu Y; Chen H; Zhou C
    J Hosp Infect; 2021 Dec; 118():40-47. PubMed ID: 34560168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
    Chu HP; Brind J; Tomar R; Hill S
    J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis.
    van den Bosch CH; Jeremiasse B; van der Bruggen JT; Frakking FNJ; Loeffen YGT; van de Ven CP; van der Steeg AFW; Fiocco MF; van de Wetering MD; Wijnen MHWA
    J Hosp Infect; 2022 May; 123():143-155. PubMed ID: 34767871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of taurolidine locks to prevent recurrent catheter-related blood stream infections in adult patients receiving home parenteral nutrition: a 2-year mirror-image study.
    Lannoy D; Janes A; Lenne X; Neuville S; Bourry J; Odou P; Bruandet A; Seguy D
    Clin Nutr; 2021 Jun; 40(6):4309-4315. PubMed ID: 33583660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
    Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
    Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
    Al-Ali F; Hamdy AF; Hamad A; Elsayed M; Zafar Iqbal Z; Elsayed A; Ibrahim R; Tolba H; Buanan H; Fawzy A
    Nephrol Dial Transplant; 2018 Apr; 33(4):619-626. PubMed ID: 29106676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
    Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U
    J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.